- Mereo BioPharma is a biopharma company focused on oncology and rare diseases, suiting a market cap of $388M USD at the time of this article.
- The company currently has great partnerships in place, which will increase the chances of success as well as my confidence as an investor.
- Mereo has a fairly diversified portfolio and a management that has been executing on both the development, and financial side.
- Overall, as being a London-based company, I do believe Mereo is overlooked, and deserves more recognition and value for the pipeline, partnerships, and strong balance sheet they currently have.
For further details see:
Mereo BioPharma: An Overlooked Bio Company